Intelligent Bio Solutions Inc. Reports First Quarter Ending September 30, 2022, Preliminary Financial Results and Recent Business Highlights
-
- Announced new additions to Board of Directors and name change to
- Company to host conference call & webcast today at
“As reflected in our name change to Intelligent Bio Solutions, this last quarter represents a sea change in the growth and evolution of the Company with the highly synergistic acquisition of
First Quarter Highlights, Recent Operational Developments
Strategic Partnerships &
- Concurrent with our name change to Intelligent Bio Solutions, we announced the full acquisition of IFP, expanding the Company’s portfolio to now include its Biosensor saliva test and IFP’s rapid, non-invasive, sweat-based fingerprint diagnostic platform for conveniently detecting drugs of abuse on-site, while also adding to and accelerating revenue growth.
- Intelligent Bio Solutions continues to advance towards the next phase of the Biosensor development program with two key parallel clinical studies: the first study focusing on eliminating the variables affecting glucose levels in saliva and in the sample collection method; and the second study assessing the accuracy and reproducibility of measuring saliva glucose with the Biosensor test strip.
Business Development
- In October, Intelligent Bio Solutions announced a new relationship with
Goldstar Transport for transitioning from urine to fingerprint drug testing. Goldstar, which employs approximately 600 LGV drivers, 170 office staff and 40 container lifter staff, purchased six Intelligent Fingerprinting portable readers and has been conducting random drug tests each month, across its 14 siteUK -wide operations, to adhere to FORS (Fleet Operator Recognition Scheme) guidelines, whilst also using the in-house system to support for cause testing. - In November, Intelligent Bio Solutions announced that
Eastern Airways has adopted its innovative fingerprint drug test for use from flight crews to maintenance personnel, in order to promote adherence to the company’s Drug and Alcohol policy and to help ensure employees are fit-to-work. The change also aims to ensure Eastern Airways’ compliance withEuropean Aviation Authority regulations to promote staff wellbeing and support.Eastern Airways is an award-winning, leading provider of private air charter flights and short-haul flights across theUK andNorthern Ireland . - Also in November, Intelligent Bio Solutions announced that
The Glass Systems Group is adopting its fingerprint-based drug testing system to promote health and safety across the business.The Glass Systems Group is the largest independent glass manufacturer in theUK with plants inWales ,Scotland , andEngland .The Glass Systems Group intends to rollout random drug testing based on the Intelligent Fingerprinting solution across itsUK operations, currently consisting of six factories and 1,000 employees.
Commercial Development
- Intelligent Bio Solutions is progressing in its construction of the previously announced, state-of-the-art manufacturing facility at
University of Newcastle inAustralia specifically to produce its proprietary biosensor.
Governance
- In October, Intelligent Bio Solutions announced two key additions to its Board of Directors with the appointment of Mr.
David Jenkins and Mr.Jason Isenberg to its Board..Mr. Jenkins is a serial entrepreneur in the medical device sector, having established numerous companies including Catheter Precision, where he currently serves as CEO and Board Chair.Mr. Jenkins has been instrumental in several strategic transactions including the acquisition of Arrhythmia Research Technology’s Cardiolab, the first dual monitor, 32-channel electrophysiology recording system, by General Electric and the sale ofEP MedSystems, Inc. , toSt. Jude Medical, Inc. , now part ofAbbott , for approximately$95.7 million in 2008.Mr. Jenkins holds a degree in accounting from theUniversity of Kansas , and a master’s degree in business from theUniversity of Texas ,Austin . He began his career in public accounting with the firmCoopers & Lybrand .
Mr.Jason Isenberg currently serves as Assistant General Counsel forRFA Management Company, LLC inAtlanta, Georgia , where he advises a large, endowment-style portfolio in matters including corporate governance, corporate and real estate transactions, business operations, employment law and risk mitigation. Jason successfully negotiated strategic transactions exceeding$500,000,000 . He obtained his Bachelor of Arts from theUniversity of Maryland and his juris doctor from New England Law inBoston .
Anticipated Events and Targeted Milestones for the Coming Fiscal Year
- Launching the Intelligent Fingerprint Drug screening solutions within the Australian and
New Zealand markets. This will include all the required infrastructure and regulatory requirements. - Continue to develop the Biosensor to test glucose, moving forward in parallel for hormone testing, focusing initially on cortisol, to be included in our next series of clinical trials anticipated to start before calendar end 2022.
1. The second round of equipment for our labs, the Polymer synthesis and characterization work cells, are now on-site. We will have also completed the Installation and Equipment Qualification by the end of November.
- Progression into the final design and verification phase of the Biosensor development with two key parallel clinical studies based on results of the recently completed blood and saliva glucose study:
1. Study 1: Elimination of variables affecting glucose levels in saliva and in the sample collection method anticipated to commence inNovember 2022 and expected to complete in approximately six months; and
2. Study 2: Assessing accuracy and reproducibility of glucose testing with the Biosensor test strip, expected to commence, as guided, in the calendar fourth quarter of year-end 2022
Both studies, together, are intended to refine saliva collection protocols and enhance the Biosensor performance as we finalize product design and shift from R&D to manufacturing.
- Confirmation of the Biosensor algorithm, middleware and application development with the
University of Newcastle inAustralia , and data generation for regulatory submission to theU.S. Food and Drug Administration (the “FDA”). - Defining the scope of work for expansion of the Biosensor platform to include additional analytes, in parallel to glucose, for point of care testing using saliva.
- IFP products to focus on increasing sales into
UK , mainlandEurope , theAsia Pacific region and non-FDA regulated markets in the US with significant potential. - Submission of FDA application for the IFP DSR system.
First Quarter Ended
As of
The major components of outflows were expenditure relating to the proposed pilot manufacturing facility in
For the quarter ended,
Government support income was
The Company is of the view that based on the current operating plan and financial resources, its cash, cash equivalents and marketable securities as of
Webcast Information:
| Title: | |||
| Date: | |||
| Time: | |||
| Conference Call Details: | Toll-Free: 1-877-300-8521 International: 1-412-317-6026 Conference ID: 10172375 |
||
| The conference call will be webcast live from the Company’s website and will be available via the following links: |
|||
| Webcast: | Webcast Registration Link https://investors.gbs.inc/news-and-events/investor-calendar |
||
The webcast should be accessed 15 minutes prior to the conference call start time.
A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the IR section of the Company’s website.
Forward-Looking Statements:
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.’s ability to consummate the proposed transaction described in this press release, develop and commercialize its diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions’ public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
About
Company Contact:
Investor.Relations@gbs.inc
Media Contact:
cheryl.billson@commacomms.com
INTELLIGENT BIO SOLUTIONS INC.
PRELIMINARY CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(UNAUDITED)
(Amounts in $)
| Three Months Ended |
||||||||
| 2022 | 2021 | |||||||
| Revenue: | ||||||||
| Other income: | ||||||||
| Government support income | $ | 311,320 | $ | - | ||||
| Total revenue and other income | 311,320 | - | ||||||
| Operating expenses: | ||||||||
| General and administrative expenses | 1,450,418 | 1,332,520 | ||||||
| Development and regulatory approval expenses | 79,274 | 106,799 | ||||||
| Total operating expenses | 1,529,692 | 1,439,319 | ||||||
| Loss from operations | (1,218,372 | ) | (1,439,319 | ) | ||||
| Other income (expense): | ||||||||
| Interest expense | (1,065 | ) | - | |||||
| Realized foreign exchange loss | (2,247 | ) | (3,118 | ) | ||||
| Interest income | 7,606 | 4,597 | ||||||
| Total other income (expense) | 4,294 | 1,479 | ||||||
| Net loss | (1,214,078 | ) | (1,437,840 | ) | ||||
| Net loss attributable to non-controlling interest | (5,785 | ) | (5,188 | ) | ||||
| Net loss attributable to |
$ | (1,208,293 | ) | $ | (1,432,652 | ) | ||
| Other comprehensive loss, net of tax: | ||||||||
| Foreign currency translation loss | $ | (135,559 | ) | $ | (67,482 | ) | ||
| Total other comprehensive loss | (135,559 | ) | (67,482 | ) | ||||
| Comprehensive loss | (1,349,637 | ) | (1,505,322 | ) | ||||
| Comprehensive loss attributable to non-controlling interest | (5,785 | ) | (5,188 | ) | ||||
| Comprehensive loss attributable to |
$ | (1,343,852 | ) | $ | (1,500,134 | ) | ||
| Net loss per share, basic and diluted | $ | (0.08 | ) | $ | (0.10 | ) | ||
| Weighted average shares outstanding, basic and diluted | 14,889,904 | 14,006,127 | ||||||
INTELLIGENT BIO SOLUTIONS INC.
PRELIMINARY CONSOLIDATED BALANCE SHEETS
(Unaudited)
(Amounts in $)
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 5,742,626 | $ | 8,238,301 | ||||
| Deferred charges | 300,000 | - | ||||||
| Grant receivable, current portion | 1,443,939 | 1,529,882 | ||||||
| Research and development tax incentive receivable | 571,860 | 353,048 | ||||||
| Other current assets | 148,927 | 746,761 | ||||||
| Total current assets | 8,207,352 | 10,867,992 | ||||||
| Long-term grant receivable | 1,031,384 | 1,092,773 | ||||||
| Construction in progress | 416,029 | 391,408 | ||||||
| Other non-current assets | 504,938 | - | ||||||
| TOTAL ASSETS | $ | 10,159,703 | $ | 12,352,173 | ||||
| LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable and accrued expenses | $ | 1,038,545 | $ | 1,625,089 | ||||
| Current portion of deferred grant income | 1,018,918 | 2,836,582 | ||||||
| Current employee benefit liabilities | 299,686 | 201,332 | ||||||
| Total current liabilities | 2,357,149 | 4,663,003 | ||||||
| Employee benefit liabilities | 20,791 | 50,626 | ||||||
| Long-term deferred grant income | 2,585,629 | 1,092,773 | ||||||
| Total liabilities | 4,963,569 | 5,806,402 | ||||||
| Commitments and contingencies | ||||||||
| Shareholders' equity: | ||||||||
| Common stock, |
148,899 | 148,899 | ||||||
| Additional paid-in capital | 38,440,011 | 38,440,011 | ||||||
| Accumulated deficit | (32,384,146 | ) | (31,175,853 | ) | ||||
| Accumulated other comprehensive loss | (923,694 | ) | (788,135 | ) | ||||
| Total consolidated |
5,281,070 | 6,624,922 | ||||||
| Non-controlling interest | (84,936 | ) | (79,151 | ) | ||||
| Total shareholders' equity | 5,196,134 | 6,545,771 | ||||||
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | $ | 10,159,703 | $ | 12,352,173 | ||||
Source: Intelligent Bio Solutions, Inc.